Desmoteplase in Acute Ischemic Stroke (DIAS)
Completed
Phase 2 Results N/ASummary of Purpose
The DIAS study (Part 2) was performed to support the dose finding of desmoteplase treatment in subjects with acute ischemic stroke selected by perfusion/diffusion mismatch on MRI within a time window of 3 to 9 h after stroke-symptom onset. In addition, it assessed safety and tolerability of 3 doses of desmoteplase compared with placebo with special consideration of intracranial hemorrhage and major systemic...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 12 March 2008.
1 Mar 2001 | 12 Mar 2008 | 1 Oct 2003 | 1 Oct 2003 | 1 Mar 2008 | Unavailable |
Start Date | First Received | 1st Completion | Completion | Verification | Results |
---|
Trial Basics
Interventions
Conditions
Sponsors
Trial Design
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator)
- Purpose: Treatment
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Contacts
Not available
View Trial Locations
Recruitment
- Enrollment: 104
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 1 location, 1 country
Principal Investigator
- Werner Hacke, Prof. Dr.
Head of Neurology Department, University of Heidelberg